Novimmune SA
Novimmune SA, headquartered in Switzerland (CH), is a pioneering biotechnology company specialising in the development of innovative therapeutic antibodies. Founded in 2007, Novimmune has made significant strides in the biopharmaceutical industry, focusing on areas such as oncology and autoimmune diseases. The company is renowned for its proprietary antibody discovery platform, which enables the creation of unique, high-affinity antibodies tailored to target specific disease mechanisms. Novimmune's commitment to advancing healthcare is reflected in its robust pipeline of clinical candidates, positioning it as a key player in the global biotechnology landscape. With a strong emphasis on research and development, Novimmune continues to achieve notable milestones, contributing to the evolution of targeted therapies and improving patient outcomes worldwide.
DitchCarbon Score
How does Novimmune SA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novimmune SA's score of 26 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Novimmune SA's reported carbon emissions
In 2019, Novimmune SA reported total carbon emissions of approximately 4,070,000 kg CO2e, with emissions distributed across various scopes: 100,000 kg CO2e from Scope 1, 155,000 kg CO2e from Scope 2, and a significant 4,000,000 kg CO2e from Scope 3. This marked a notable increase in emissions compared to previous years, particularly in Scope 3, which reflects the broader impact of their supply chain and product lifecycle. In 2018, the company emitted about 981,000 kg CO2e in Scope 3, alongside 129,000 kg CO2e in Scope 1 and 213,000 kg CO2e in Scope 2. The trend shows a gradual increase in emissions over the years, with 2017 reporting 830,000 kg CO2e in Scope 3, 159,000 kg CO2e in Scope 1, and 221,000 kg CO2e in Scope 2. Despite the rising emissions, Novimmune has not publicly disclosed specific reduction targets or initiatives aimed at mitigating their carbon footprint. The absence of documented reduction strategies suggests a need for enhanced climate commitments in line with industry standards. As a company headquartered in Switzerland (CH), Novimmune is positioned within a region increasingly focused on sustainability and climate action, which may influence future commitments and strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| Scope 1 | - | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 236,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 861,000 | 000,000 | 000,000 | 000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novimmune SA is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
